Cardiome Pharma Stock Price, News & Analysis (NASDAQ:CRME)

$1.50 -0.09 (-5.66 %)
(As of 12/12/2017 04:00 PM ET)
Previous Close$1.59
Today's Range$1.48 - $1.65
52-Week Range$1.29 - $4.84
Volume227,700 shs
Average Volume111,291 shs
Market Capitalization$55.06 million
P/E RatioN/A
Dividend YieldN/A
Beta0.81

About Cardiome Pharma (NASDAQ:CRME)

Cardiome Pharma logoCardiome Pharma Corp. (Cardiome) is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of cardiovascular therapies for heart disease. The Company's segments are Europe and Rest of World. Cardiome has two marketed, in-hospital, cardiology products, which include BRINAVESS (vernakalant IV), approved in Europe and other territories for the conversion of onset atrial fibrillation (AF) to sinus rhythm in adults, and AGGRASTAT (tirofiban hydrochloride (HCl)), indicated for use in patients with acute coronary syndrome. Cardiome also commercializes ESMOCARD and ESMOCARD LYO (esmolol hydrochloride), a short-acting beta-blocker used to control heart rate in various cardiovascular indications, in select European markets. Cardiome has also licensed TREVYENT, a development-stage drug device combination product that is under development for pulmonary arterial hypertension, in certain regions outside the United States.

Receive CRME News and Ratings via Email

Sign-up to receive the latest news and ratings for CRME and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biopharmaceuticals
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CRME
CUSIPN/A
Phone604-677-6905

Debt

Debt-to-Equity Ratio1.67%
Current Ratio5.52%
Quick Ratio4.71%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$25.26 million
Price / Sales2.06
Cash FlowN/A
Price / CashN/A
Book Value$1.07 per share
Price / Book1.40

Profitability

Trailing EPS($0.84)
Net Income$-19,610,000.00
Net Margins-112.91%
Return on Equity-94.68%
Return on Assets-40.25%

Miscellaneous

Employees120
Outstanding Shares34,630,000

Cardiome Pharma (NASDAQ:CRME) Frequently Asked Questions

What is Cardiome Pharma's stock symbol?

Cardiome Pharma trades on the NASDAQ under the ticker symbol "CRME."

How were Cardiome Pharma's earnings last quarter?

Cardiome Pharma Corporation (NASDAQ:CRME) issued its quarterly earnings results on Tuesday, November, 14th. The biopharmaceutical company reported ($0.20) EPS for the quarter, missing analysts' consensus estimates of ($0.16) by $0.04. The biopharmaceutical company had revenue of $6.02 million for the quarter, compared to analysts' expectations of $7.42 million. Cardiome Pharma had a negative net margin of 112.91% and a negative return on equity of 94.68%. The firm's quarterly revenue was up 14.9% on a year-over-year basis. During the same period in the prior year, the company earned ($0.19) EPS. View Cardiome Pharma's Earnings History.

When will Cardiome Pharma make its next earnings announcement?

Cardiome Pharma is scheduled to release their next quarterly earnings announcement on Tuesday, March, 6th 2018. View Earnings Estimates for Cardiome Pharma.

Where is Cardiome Pharma's stock going? Where will Cardiome Pharma's stock price be in 2017?

3 brokers have issued 12-month price objectives for Cardiome Pharma's stock. Their forecasts range from $4.75 to $9.50. On average, they anticipate Cardiome Pharma's share price to reach $6.42 in the next year. View Analyst Ratings for Cardiome Pharma.

What are Wall Street analysts saying about Cardiome Pharma stock?

Here are some recent quotes from research analysts about Cardiome Pharma stock:

  • 1. According to Zacks Investment Research, "Cardiome Pharma Corp. is a product-focused cardiovascular drug development company with two clinical drug programs focused on atrial arrhythmia (intravenous and oral dosing), and a pre-clinical program directed at improving cardiovascular function. " (11/14/2017)
  • 2. Canaccord Genuity analysts commented, "Date and time of first dissemination: August 21, 2017, 09:42 ET Date and time of production: August 21, 2017, 09:42 ET Target Price / Valuation Methodology: Cardiome Pharma Corp. – CRME Discounted cash flow analysis supports an $8 valuation for CRME shares Our discounted cash flow (DCF) analysis leads us to a 12-month valuation of around $8/share for CRME, assuming continued progress on the Brinavess Canada and Xydalba launches along with a potential Trevyent launch in 2019. We estimate a weighted average cost of capital (WACC) of 11.2%, which assumes an 88% equity/total capital structure at a 10.3% cost of equity capital and a 12% debt/total capital structure at a 14% cost of debt. We use a long-term estimated tax rate of 22% and a terminal growth decline of 1% in our analysis. For cash management purposes, our analysis assumes an equity raise in 2H/17 but management has not publicly commented on the possibility of future capital raises. Risks to achieving Target Price / Valuation: Cardiome Pharma Corp. – CRME OUS payers and providers can be more difficult to predict – Given the relative lack of market data compared to the US coupled with a fragmented payer landscape, variability in physician training and standard of care modalities, and different preferences in patient populations in OUS markets, the marketability of a product in these environments can be more difficult to predict than in the US." (8/21/2017)

Who are some of Cardiome Pharma's key competitors?

Who are Cardiome Pharma's key executives?

Cardiome Pharma's management team includes the folowing people:

  • W. James O'Shea, Independent Chairman of the Board
  • William L. Hunter M.D., President, Chief Executive Officer, Director (Age 52)
  • Justin A. Renz C.P.A., M.S.T., M.B., Chief Financial Officer (Age 45)
  • Sheila M. Grant, Chief Operating Officer
  • David D. McMasters J.D., Corporate General Counsel
  • David C. Dean, Chief Business Development Officer
  • Jennifer Archibald CPA, Chief Business Operations Officer
  • Hugues Sachot, Chief Commercial Officer
  • Richard M. Glickman LL.D., Lead Independent Director (Age 57)
  • Mark H.N. Corrigan M.D., Independent Director (Age 60)

Who owns Cardiome Pharma stock?

Cardiome Pharma's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Westfield Capital Management Co. LP (14.37%), WESTFIELD CAPITAL MANAGEMENT COMPANY LP (13.74%) and Stonepine Capital Management LLC (8.48%). View Institutional Ownership Trends for Cardiome Pharma.

Who sold Cardiome Pharma stock? Who is selling Cardiome Pharma stock?

Cardiome Pharma's stock was sold by a variety of institutional investors in the last quarter, including Westfield Capital Management Co. LP. View Insider Buying and Selling for Cardiome Pharma.

Who bought Cardiome Pharma stock? Who is buying Cardiome Pharma stock?

Cardiome Pharma's stock was bought by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC. View Insider Buying and Selling for Cardiome Pharma.

How do I buy Cardiome Pharma stock?

Shares of Cardiome Pharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cardiome Pharma's stock price today?

One share of Cardiome Pharma stock can currently be purchased for approximately $1.50.

How big of a company is Cardiome Pharma?

Cardiome Pharma has a market capitalization of $55.06 million and generates $25.26 million in revenue each year. The biopharmaceutical company earns $-19,610,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis. Cardiome Pharma employs 120 workers across the globe.

How can I contact Cardiome Pharma?

Cardiome Pharma's mailing address is 1441 Creekside Drive 6th Floor, Vancouver A1, V6J 4S7. The biopharmaceutical company can be reached via phone at 604-677-6905 or via email at [email protected]


MarketBeat Community Rating for Cardiome Pharma (CRME)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  162 (Vote Outperform)
Underperform Votes:  157 (Vote Underperform)
Total Votes:  319
MarketBeat's community ratings are surveys of what our community members think about Cardiome Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Cardiome Pharma (NASDAQ:CRME) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.832.832.832.83
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $5.95$6.65$6.65$7.05
Price Target Upside: 291.45% upside155.77% upside155.77% upside128.90% upside

Cardiome Pharma (NASDAQ:CRME) Consensus Price Target History

Price Target History for Cardiome Pharma (NASDAQ:CRME)

Cardiome Pharma (NASDAQ:CRME) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/22/2017HC WainwrightReiterated RatingBuy$9.50N/AView Rating Details
11/15/2017Canaccord GenuitySet Price TargetBuy -> Buy$8.00 -> $5.00N/AView Rating Details
12/22/2016Leerink SwannInitiated CoverageOutperform$4.75N/AView Rating Details
11/9/2016Bloom BurtonReiterated RatingBuyN/AView Rating Details
10/12/2016MackieReiterated RatingSpeculative Buy -> Hold$5.10 -> $3.50N/AView Rating Details
8/15/2016Brean CapitalReiterated RatingBuy$10.00 -> $7.00N/AView Rating Details
(Data available from 12/12/2015 forward)

Earnings

Cardiome Pharma (NASDAQ:CRME) Earnings History and Estimates Chart

Earnings by Quarter for Cardiome Pharma (NASDAQ:CRME)

Cardiome Pharma (NASDAQ CRME) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/6/2018        
11/14/2017n/a($0.16)($0.20)$7.42 million$6.02 millionViewN/AView Earnings Details
8/8/20176/30/2017($0.18)($0.26)$6.88 million$5.75 millionViewListenView Earnings Details
5/15/20173/31/2017($0.15)($0.20)$6.96 million$5.19 millionViewN/AView Earnings Details
3/7/2017Q4($0.16)($0.18)$6.72 million$7.00 millionViewListenView Earnings Details
11/7/2016Q316($0.20)($0.19)$5.68 million$5.20 millionViewListenView Earnings Details
8/9/2016Q216($0.19)($0.37)$6.73 million$5.90 millionViewN/AView Earnings Details
5/13/2016Q116($0.21)($0.06)$6.34 million$7.10 millionViewListenView Earnings Details
3/10/2016Q415($0.19)($0.37)$7.74 million$4.70 millionViewListenView Earnings Details
11/13/2015Q315($0.23)($0.31)$7.08 million$5.00 millionViewListenView Earnings Details
8/5/2015Q215($0.25)($0.43)$7.67 million$5.70 millionViewN/AView Earnings Details
5/13/2015Q115($0.28)($0.23)$7.48 million$5.50 millionViewListenView Earnings Details
3/12/2015Q414($0.14)($0.39)$8.54 million$7.00 millionViewN/AView Earnings Details
11/7/2014Q314($0.13)($0.26)$6.20 million$7.81 millionViewN/AView Earnings Details
8/11/2014Q2 2014($0.16)($0.26)$6.77 million$7.67 millionViewN/AView Earnings Details
5/12/2014Q114($0.11)($0.20)$8.08 million$7.60 millionViewN/AView Earnings Details
3/27/2014($0.22)($0.53)ViewN/AView Earnings Details
11/6/2013Q3 13($0.21)($0.29)ViewN/AView Earnings Details
8/2/2013Q2 13($0.19)($0.22)ViewN/AView Earnings Details
5/13/2013Q113$1.48$1.47$1.60 millionViewN/AView Earnings Details
3/15/2013Q412($0.05)$0.13$0.84 millionViewN/AView Earnings Details
11/13/2012Q312($0.11)($0.22)ViewN/AView Earnings Details
11/4/2011($0.10)($0.12)ViewN/AView Earnings Details
5/16/2011($0.11)($0.12)ViewN/AView Earnings Details
3/10/2011($0.08)($0.12)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Cardiome Pharma (NASDAQ:CRME) Earnings Estimates

2017 EPS Consensus Estimate: ($0.54)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.12)($0.09)($0.11)
Q2 20172($0.16)($0.14)($0.15)
Q3 20172($0.13)($0.12)($0.13)
Q4 20172($0.17)($0.15)($0.16)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Cardiome Pharma (NASDAQ:CRME)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Cardiome Pharma (NASDAQ CRME)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Cardiome Pharma (NASDAQ CRME) News Headlines

Source:
DateHeadline
With 13.4% Earnings Drop Lately, Did Cardiome Pharma Corp (TSX:COM) Underperform Its Industry?With 13.4% Earnings Drop Lately, Did Cardiome Pharma Corp (TSX:COM) Underperform Its Industry?
finance.yahoo.com - December 11 at 5:32 PM
Cardiome Pharma Corp. :CRME-US: Earnings Analysis: Q3, 2017 By the Numbers : November 30, 2017Cardiome Pharma Corp. :CRME-US: Earnings Analysis: Q3, 2017 By the Numbers : November 30, 2017
finance.yahoo.com - November 30 at 9:58 AM
Cardiome Pharma Corporation (CRME) Stock Rating Reaffirmed by HC WainwrightCardiome Pharma Corporation (CRME) Stock Rating Reaffirmed by HC Wainwright
www.americanbankingnews.com - November 22 at 8:20 AM
Zacks: Analysts Expect Cardiome Pharma Corporation (CRME) Will Post Earnings of -$0.17 Per ShareZacks: Analysts Expect Cardiome Pharma Corporation (CRME) Will Post Earnings of -$0.17 Per Share
www.americanbankingnews.com - November 19 at 7:10 PM
Canaccord Genuity Analysts Give Cardiome Pharma Corporation (CRME) a $5.00 Price TargetCanaccord Genuity Analysts Give Cardiome Pharma Corporation (CRME) a $5.00 Price Target
www.americanbankingnews.com - November 19 at 4:56 PM
Cardiome Pharmas (CRME) CEO William Hunter on Q3 2017 Results - Earnings Call TranscriptCardiome Pharma's (CRME) CEO William Hunter on Q3 2017 Results - Earnings Call Transcript
seekingalpha.com - November 15 at 4:45 AM
Cardiome Pharma Corporation (CRME) Releases  Earnings Results, Misses Expectations By $0.04 EPSCardiome Pharma Corporation (CRME) Releases Earnings Results, Misses Expectations By $0.04 EPS
www.americanbankingnews.com - November 14 at 9:34 PM
Cardiome Pharma Corporation (CRME) Lowered to Hold at Zacks Investment ResearchCardiome Pharma Corporation (CRME) Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - November 14 at 9:10 PM
Cardiome Pharma Corp. to Host Earnings CallCardiome Pharma Corp. to Host Earnings Call
finance.yahoo.com - November 14 at 5:55 PM
Cardiome Reports Third Quarter 2017 Financial ResultsCardiome Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 14 at 5:55 PM
Cardiome Pharma Corporation (CRME) Set to Announce Earnings on TuesdayCardiome Pharma Corporation (CRME) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - November 8 at 10:14 AM
Analyzing Cardiome Pharma Corporation (CRME) and Mirna Therapeutics (SYBX)Analyzing Cardiome Pharma Corporation (CRME) and Mirna Therapeutics (SYBX)
www.americanbankingnews.com - November 6 at 3:15 PM
Cardiome Pharma Corporation (CRME) Given Average Recommendation of "Buy" by BrokeragesCardiome Pharma Corporation (CRME) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - November 5 at 1:40 PM
Cardiome Pharma Corporation (CRME) Upgraded at Zacks Investment ResearchCardiome Pharma Corporation (CRME) Upgraded at Zacks Investment Research
www.americanbankingnews.com - November 1 at 7:08 PM
$8.04 Million in Sales Expected for Cardiome Pharma Corporation (CRME) This Quarter$8.04 Million in Sales Expected for Cardiome Pharma Corporation (CRME) This Quarter
www.americanbankingnews.com - November 1 at 2:32 PM
Head-To-Head Review: Syros Pharmaceuticals (SYRS) and Cardiome Pharma Corporation (CRME)Head-To-Head Review: Syros Pharmaceuticals (SYRS) and Cardiome Pharma Corporation (CRME)
www.americanbankingnews.com - October 16 at 9:18 AM
Cardiome Pharma Corporation (CRME) Receives Consensus Rating of "Hold" from BrokeragesCardiome Pharma Corporation (CRME) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - October 11 at 5:04 PM
Cardiome Pharma Corporation (CRME) Upgraded to Hold at Zacks Investment ResearchCardiome Pharma Corporation (CRME) Upgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - October 11 at 12:04 AM
Anika Therapeutics (ANIK) and Cardiome Pharma Corporation (CRME) Critical ComparisonAnika Therapeutics (ANIK) and Cardiome Pharma Corporation (CRME) Critical Comparison
www.americanbankingnews.com - October 8 at 8:08 PM
Contrasting Argos Therapeutics (ARGS) and Cardiome Pharma Corporation (CRME)Contrasting Argos Therapeutics (ARGS) and Cardiome Pharma Corporation (CRME)
www.americanbankingnews.com - October 1 at 4:38 PM
Cardiome Pharma Corporation (CRME) Expected to Post Quarterly Sales of $8.04 MillionCardiome Pharma Corporation (CRME) Expected to Post Quarterly Sales of $8.04 Million
www.americanbankingnews.com - September 24 at 3:22 AM
Critical Comparison: Cardiome Pharma Corporation (CRME) versus Its RivalsCritical Comparison: Cardiome Pharma Corporation (CRME) versus Its Rivals
www.americanbankingnews.com - September 21 at 10:14 AM
Financial Review: Cardiome Pharma Corporation (CRME) and Its PeersFinancial Review: Cardiome Pharma Corporation (CRME) and Its Peers
www.americanbankingnews.com - September 17 at 4:26 AM
Cardiome Pharma Corporation (CRME) Given Average Rating of "Hold" by BrokeragesCardiome Pharma Corporation (CRME) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - September 16 at 3:00 PM
Cardiome Pharma Corp. :CRME-US: Earnings Analysis: Q2, 2017 By the Numbers : September 13, 2017Cardiome Pharma Corp. :CRME-US: Earnings Analysis: Q2, 2017 By the Numbers : September 13, 2017
finance.yahoo.com - September 13 at 6:47 PM
Cardiome, Pipeline Offers Opportunities Beyond BrinavessCardiome, Pipeline Offers Opportunities Beyond Brinavess
finance.yahoo.com - September 6 at 5:32 PM
$7.80 Million in Sales Expected for Cardiome Pharma Corporation (CRME) This Quarter$7.80 Million in Sales Expected for Cardiome Pharma Corporation (CRME) This Quarter
www.americanbankingnews.com - September 5 at 1:56 AM
 Brokerages Anticipate Cardiome Pharma Corporation (CRME) Will Announce Earnings of -$0.17 Per Share Brokerages Anticipate Cardiome Pharma Corporation (CRME) Will Announce Earnings of -$0.17 Per Share
www.americanbankingnews.com - September 3 at 10:24 PM
Cardiome Pharma (CRME) Says New Data Presented at ESC Highlights Clinical Benefit of BRINAVESSCardiome Pharma (CRME) Says New Data Presented at ESC Highlights Clinical Benefit of BRINAVESS
www.streetinsider.com - August 30 at 6:37 PM
Cardiome Pharma Corporation (CRME) vs. Kamada (KMDA) Head to Head ContrastCardiome Pharma Corporation (CRME) vs. Kamada (KMDA) Head to Head Contrast
www.americanbankingnews.com - August 29 at 12:22 AM
Cardiome not quite there on resubmission of Brinavess NDA; shares down 5% premarketCardiome not quite there on resubmission of Brinavess NDA; shares down 5% premarket
seekingalpha.com - August 23 at 4:11 AM
Cardiome Pharma Corporation (CRME) Receives Consensus Recommendation of "Hold" from AnalystsCardiome Pharma Corporation (CRME) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - August 22 at 4:56 PM
Financial Comparison: Cardiome Pharma Corporation (CRME) versus VIVUS (VVUS)Financial Comparison: Cardiome Pharma Corporation (CRME) versus VIVUS (VVUS)
www.americanbankingnews.com - August 22 at 10:32 AM
Canaccord Genuity Analysts Give Cardiome Pharma Corporation (CRME) a $8.00 Price TargetCanaccord Genuity Analysts Give Cardiome Pharma Corporation (CRME) a $8.00 Price Target
www.americanbankingnews.com - August 21 at 6:02 PM
 Brokerages Expect Cardiome Pharma Corporation (CRME) Will Announce Quarterly Sales of $7.80 Million Brokerages Expect Cardiome Pharma Corporation (CRME) Will Announce Quarterly Sales of $7.80 Million
www.americanbankingnews.com - August 18 at 11:16 AM
 Analysts Expect Cardiome Pharma Corporation (CRME) Will Announce Earnings of -$0.17 Per Share Analysts Expect Cardiome Pharma Corporation (CRME) Will Announce Earnings of -$0.17 Per Share
www.americanbankingnews.com - August 16 at 10:16 AM
Cormark Analysts Reduce Earnings Estimates for Cardiome Pharma Corporation (NASDAQ:CRME)Cormark Analysts Reduce Earnings Estimates for Cardiome Pharma Corporation (NASDAQ:CRME)
www.americanbankingnews.com - August 11 at 9:26 AM
Cardiome Pharma Corporation (CRME) Releases  Earnings Results, Misses Expectations By $0.09 EPSCardiome Pharma Corporation (CRME) Releases Earnings Results, Misses Expectations By $0.09 EPS
www.americanbankingnews.com - August 8 at 6:30 PM
Cardiome Pharma Corporation (NASDAQ:CRME) Scheduled to Post Quarterly Earnings on TuesdayCardiome Pharma Corporation (NASDAQ:CRME) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - August 3 at 10:40 AM
$6.97 Million in Sales Expected for Cardiome Pharma Corporation (CRME) This Quarter$6.97 Million in Sales Expected for Cardiome Pharma Corporation (CRME) This Quarter
www.americanbankingnews.com - July 31 at 9:41 AM
-$0.18 Earnings Per Share Expected for Cardiome Pharma Corporation (NASDAQ:CRME) This Quarter-$0.18 Earnings Per Share Expected for Cardiome Pharma Corporation (NASDAQ:CRME) This Quarter
www.americanbankingnews.com - July 29 at 7:46 AM
Cardiome Pharma Corporation (CRME) Given Average Rating of "Buy" by AnalystsCardiome Pharma Corporation (CRME) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - July 28 at 2:31 PM
Cardiome Announces Health Canada Approval of AGGRASTAT® High Dose Bolus RegimenCardiome Announces Health Canada Approval of AGGRASTAT® High Dose Bolus Regimen
finance.yahoo.com - July 17 at 5:52 PM
Cardiome Pharma Corporation (CRME) Earns "Buy" Rating from Canaccord GenuityCardiome Pharma Corporation (CRME) Earns "Buy" Rating from Canaccord Genuity
www.americanbankingnews.com - July 17 at 10:39 AM
$6.97 Million in Sales Expected for Cardiome Pharma Corporation (NASDAQ:CRME) This Quarter$6.97 Million in Sales Expected for Cardiome Pharma Corporation (NASDAQ:CRME) This Quarter
www.americanbankingnews.com - July 7 at 4:29 PM
 Analysts Anticipate Cardiome Pharma Corporation (CRME) Will Post Earnings of -$0.18 Per Share Analysts Anticipate Cardiome Pharma Corporation (CRME) Will Post Earnings of -$0.18 Per Share
www.americanbankingnews.com - July 5 at 9:12 AM
Cardiome Pharma Corporation (CRME) Receives Consensus Recommendation of "Buy" from AnalystsCardiome Pharma Corporation (CRME) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - July 3 at 2:49 PM
Cardiome Pharma (CRME) Names Justin Renz as CFO; Jennifer Archibald Appointed Chief Business Operations OfficerCardiome Pharma (CRME) Names Justin Renz as CFO; Jennifer Archibald Appointed Chief Business Operations Officer
www.streetinsider.com - May 17 at 11:30 AM
Cardiome cleared to commercialize Brinavess in Canada; shares ahead 2%Cardiome cleared to commercialize Brinavess in Canada; shares ahead 2%
seekingalpha.com - March 14 at 11:24 PM
Cardiome Pharma (CRME) Receives Notice of Compliance for BRINAVESS from Health CanadaCardiome Pharma (CRME) Receives Notice of Compliance for BRINAVESS from Health Canada
www.streetinsider.com - March 14 at 6:22 PM

SEC Filings

Cardiome Pharma (NASDAQ:CRME) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Cardiome Pharma (NASDAQ:CRME) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Cardiome Pharma (NASDAQ CRME) Stock Chart for Tuesday, December, 12, 2017

Loading chart…

This page was last updated on 12/12/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.